COVID-19 oral drug significantly reduces infection mortality in the elderly
- Paternal Microbiome Perturbations Impact Offspring Fitness
- New Report Casts Doubt on Maradona’s Cause of Death and Rocks Manslaughter Case
- Chinese academician unable to provide the exact source of liver transplants
- Early Biomarker for Multiple Sclerosis Development Identified Years in Advance
- Aspirin Found Ineffective in Improving Recurrence Risk or Survival Rate of Breast Cancer Patients
- Child Products from Aliexpess and Temu Contain Carcinogens 3026x Over Limit
COVID-19 oral drug significantly reduces infection mortality in the elderly
- AstraZeneca Admits for the First Time that its COVID Vaccine Has Blood Clot Side Effects
- Was COVID virus leaked from the Chinese WIV lab?
- HIV Cure Research: New Study Links Viral DNA Levels to Spontaneous Control
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
The Lancet: COVID-19 oral drug significantly reduces infection mortality in the elderly.
On October 8, The Lancet published an article “Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study”, which is the largest real-world study on the effectiveness of two COVID-19 oral drugs in the treatment of Omicron variant strain infection.
Source: DOI: https://doi.org/10.1016/S0140-6736(22)01586-0
The research data comes from 1,074,856 community-infected patients in Hong Kong in 2022.
After screening, 4,983 molnupiravir users and 5,542 Paxlovid users were included in the statistics, of which 9,176 were older than 60 years old (87.1%) and completed the full course of vaccination. of only 2,650 (22.4%) .
That is to say, most of them belong to the high-risk group of COVID-19 infection – advanced age and unvaccinated.
The study found that the use of two COVID-19 drugs in the early stage of infection can significantly reduce the risk of disease progression and death in the elderly. Among them, the COVID-19 oral drug Paxlovid reduced the risk of death after hospitalization in the elderly by 79%.
Source: DOI: https://doi.org/10.1016/S0140-6736(22)01586-0
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.